Table 3.
Metabolic syndrome rates for VASI and VIDA groups according to NCEP-ATPIII and IDF criteria
| Groups | NCEP-ATPIII metabolic syndrome positive (58/155) (37.4%) | p-Value | IDF metabolic syndrome positive (62/155) (40%) | p-Value |
|---|---|---|---|---|
| VASI Groups, n (%) | 0.006 | 0.013 | ||
| Group 1 (<1.94) | 10/155 (6.45%) | 12/155 (7.7%) | ||
| Group 2 (1.94–6.89) | 23/155 (14.8%) | 25/155 (16.1) | ||
| Group 3 (>6.89) | 25/155 (16.1%) | 25/155 (16.1%) | ||
| VIDA Groups, n (%) | < 0.001 | <0.001 | ||
| Group A (−1–0) | 1/155 (0.6%) | 1/155 (0.6%) | ||
| Group B (1–2) | 3/155 (1.9%) | 4/155 (2.6%) | ||
| Group C (3–4) | 54/155 (34.8%) | 57/155 (36.8%) | ||
NCEP-ATPIII, National Cholesterol Education Program Adult Treatment Panel III; IDF, The International Diabetes Federation; VASI, Vitiligo area severity index; VIDA, Vitiligo Disease Activity Score.